LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4322-4327

  Vouillamoz, Jacques ^a   Entenza, José M ^a   Hohl, Peter ^b   Moreillon, Philippe ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; LB 11058; PENICILLIN BINDING PROTEIN 2A; PENICILLINASE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG PROTEIN BINDING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; TREATMENT OUTCOME;

ANIMALS; CEPHALOSPORINS; DRUG DELIVERY SYSTEMS; ENDOCARDITIS, BACTERIAL; INFUSION PUMPS; KINETICS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; PENICILLINASE; PROTEIN BINDING; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 7244247147     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4322-4327.2004     Document Type: Article

References (33)

1. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
2. Chambers, H. F., B. J. Hartman, and A. Tomasz. 1985. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus. J. Clin. Investig. 76:325-331.
3. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 162:705-710.
4. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
5. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams and Wilkins Co., Baltimore, Md.
6. de Jonge, B. L., and A. Tomasz. 1993. Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis. Antimicrob. Agents Chemother. 37:342-346.
7. de Lencastre, H., and A. Tomasz. 1994. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2590-2598.
8. Entenza, J. M., I. Caldelari, M. P. Glauser, and P. Moreillon. 1999. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. J. Antimicrob. Chemother. 44:775-786.
9. Entenza, J. M., U. Fluckiger, M. P. Glauser, and P. Moreillon. 0994. Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J. Infect. Dis. 170:100-109.
10. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
11. Entenza, J. M., Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon. 2001. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob. Agents Chemother. 45:3076-3083.
12. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1999. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Antimicrob. Agents Chemother. 43:77-84.
13. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1662-1667.
14. Fluckiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
15. Franciolli, M., J. Bille, M. P. Glauser, and P. Moreillon. 1991. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 163:514-523.
16. Gillespie, M. T., J. W. May, and R. A. Skurray. 1985. Antibiotic resistance in Staphylococcus aureus isolated at an Australian hospital between 1946 and 1981. J. Med. Microbiol. 19:137-147.
17. Gonzalez-Zorn, B., and P. Courvalin. 2003. VanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect. Dis. 3:67-68.
18. Hakim, L., D. W. Bourne, and E. J. Triggs. 1989. Disposition of ceftriaxone in rat: application of a pharmacokinetic-protein binding model and comparison with cefotaxime. Xenobiotica 19:815-822.
19. Heraief, E., M. P. Glauser, and L. R. Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
20. Hirano, L., and A. S. Bayer. 1991. Beta-lactam-beta-lactamase inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob. Agents Chemother. 35:685-690.
21. Kusama, M., K. Yamamoto, H. Kotaki, H. Sato, and T. Iga. 1998. Effect of cilastatin on renal handling of vancomycin in rats. J. Pharm. Sci. 87:1173-1176.
22. Lim, D., and N. C. Strynadka. 2002. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. 9:870-876.
23. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
24. Malbruny, B., A. Canu, B. Bozdogan, B. Fantin, V. Zarrouk, S. Dutka-Malen, C. Feger, and R. Leclercq. 2002. Resistance to quinupristin- dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2200-2207.
25. Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:1262-1266.
26. Moreillon, P., and P. Majcherczyk. 2000. Is there still a role for penicillins and cephalosporins in the treatment of bacterial infections? Int. J. Clin. Pract. Suppl. 2000:99-105.
27. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
29. Pinho, M. G., H. de Lencastre, and A. Tomasz. 2001. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc. Natl. Acad. Sci. USA 98:10886-10891.
30. Que, Y. A., J. M. Entenza, P. Francioli, and P. Moreillon. 1998. The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 177:146-154.
31. Ramos, M. C., M. Ing, E. Kim, M. D. Witt, and A. S. Bayer. 1996. Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci. Antimicrob. Agents Chemother. 40:97-101.
32. Sader, H. S., D. M. Johnson, and R. N. Jones. 2004. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant staphylococci and streptococci. Antimicrob. Agents Chemother. 48:53-62.
33. Tomasz, A. 2003. "Intelligence coup" for drug designers: crystal structure of Staphylococcus aureus beta-lactam resistance protein PBP2A. Lancet 361: 795-796.